Here are three mental treatment updates that affect the field of behavioral health, as reported by Becker's since April 11:
1. The FDA rejected the use of MDMA as a treatment for post-traumatic stress disorder. Lykos Therapeutics, the company that developed the treatment, said in an Aug. 9 news release the FDA requested another Phase 3 trial to study the effectiveness of MDMA. Lykos plans to ask the FDA to reconsider its decision.
2. The University of Arkansas for Medical Sciences in Little Rock was the first facility in the U.S. to offer treatment for major depressive disorder using the SAINT neuromodulation system, which was cleared by the FDA for the treatment of depression in adults whose treatment has not improved from the use of antidepressants.The system, developed by Magus Medical, uses MRI scans to create an algorithm that finds the optimal target for precise transcranial magnetic stimulation.
3. The FDA cleared the first prescription digital therapeutic app, Rejoyn, for major depressive disorder. The app was developed by Otsuka America Pharmaceutical for patients 22 and older who are on antidepressant medication.